Hyperplasia is the enlargement of a tissue or organ caused by an increase in the number of its cells, rather than an increase in the size of individual cells. It is one of the most fundamental ways your body adapts to demand, whether that demand is a normal part of life or something gone wrong. The line between helpful and harmful hyperplasia depends entirely on context: the same basic process that lets your liver regrow after surgery can, in the endometrium or prostate, become a precursor to disease. Understanding where and why cell numbers ramp up reveals a lot about how your body maintains itself and where that maintenance can go sideways.
Physiological Hyperplasia and Why It Happens
Not all hyperplasia is a problem. Your body deliberately increases cell counts in response to normal, predictable demands. Breast tissue proliferates during pregnancy to prepare for milk production. The uterine lining thickens each menstrual cycle in anticipation of a fertilized egg. After a portion of the liver is surgically removed, the remaining tissue rapidly generates new cells to restore functional capacity. These are all examples of physiological hyperplasia, where the trigger is a routine biological signal and the process shuts itself off once the need is met.
What distinguishes physiological from pathological hyperplasia is essentially the nature of the trigger and whether the growth stays under control. Physiological hyperplasia responds to common, expected stressors and reverses when the stimulus disappears. Pathological hyperplasia, by contrast, arises from abnormal or sustained stimulation. An example is the adrenal glands enlarging because a pituitary tumor is pumping out excess signaling hormone, or the uterine lining thickening because estrogen is chronically elevated without the balancing influence of progesterone.
The Prostate and Hormone-Driven Growth
Benign prostatic hyperplasia, commonly called BPH, is one of the most familiar forms of the condition, affecting a large proportion of men as they age. The prostate depends on androgens for its normal development and maintenance. Testosterone produced in the testes and adrenal glands is converted into dihydrotestosterone, or DHT, which binds to receptors in prostate tissue and regulates gene activity that influences cell growth. DHT plays a constructive role in the developing prostate, but in the adult gland it can drive pathological enlargement.1PubMed. The role of dihydrotestosterone in benign prostatic hyperplasia
What makes BPH particularly interesting from a cell-biology standpoint is that the overgrowth is not simply about too many cells dividing. Research comparing normal prostate tissue with hyperplastic tissue has found that the rate of cell death through apoptosis drops substantially in BPH. In one study, the net balance between dying cells and dividing cells shifted roughly fourfold in favor of accumulation in the hyperplastic prostate compared to normal tissue. In other words, the gland grows not just because cells multiply faster but because fewer cells are cleared away through the body’s normal cleanup processes.2Human Pathology. Apoptotic versus proliferative activities in human benign prostatic hyperplasia
Treatments for BPH exploit the hormone-driven mechanism directly. Drugs called 5-alpha reductase inhibitors block the enzyme that converts testosterone to DHT. One such drug, dutasteride, inhibits both forms of this enzyme and has been shown to suppress DHT levels, improving urinary symptoms and reducing the risk of acute urinary retention or the need for surgery.3The Journal of Clinical Endocrinology & Metabolism. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor Another class, alpha-blockers like terazosin, work differently by relaxing smooth muscle in the prostate and bladder neck. Both drug classes were established as standard treatments through rigorous clinical trials in the 1990s.4PubMed Central. Medical treatment of benign prostatic hyperplasia
Endometrial Hyperplasia and the Estrogen Connection
The lining of the uterus is designed to grow and shed cyclically, but when estrogen stimulates that lining without adequate progesterone to counterbalance it, the result can be endometrial hyperplasia. This spectrum ranges from benign overgrowth of glandular tissue all the way to lesions with real potential to become cancerous.5PubMed Central. Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management The major risk factors include obesity, polycystic ovary syndrome, insulin resistance, and delayed childbearing, all of which can create states of prolonged estrogen exposure without the cyclical progesterone that would normally keep endometrial growth in check.6Trends in Immunotherapy. Immunoinflammatory and Metabolic Drivers of Endometrial Hyperplasia: From Unopposed Estrogen to Precision Medicine
Hormone therapy in postmenopausal women can trigger the same problem if estrogen is given without progesterone. A Cochrane systematic review found that unopposed estrogen therapy increased the risk of endometrial hyperplasia at all doses and across treatment durations ranging from one to three years.7PubMed Central. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia This is why modern hormone-replacement regimens for women who still have a uterus almost always include a progestogen component. The addition of progesterone essentially mimics the normal cycle’s restraining influence on endometrial growth.
At the molecular level, estrogen receptor signaling promotes cell division through pathways that accelerate progression through the cell cycle, while the loss of progesterone’s counterweight allows proliferating cells to persist rather than being shed or instructed to stop dividing.6Trends in Immunotherapy. Immunoinflammatory and Metabolic Drivers of Endometrial Hyperplasia: From Unopposed Estrogen to Precision Medicine Because endometrial hyperplasia sits on a continuum with endometrial cancer, clinicians pay close attention to biopsy results to determine whether the overgrowth shows atypical features that signal a higher risk of malignant transformation.
Compensatory Hyperplasia in the Liver
The liver’s ability to regenerate is remarkable and represents one of the clearest examples of beneficial, compensatory hyperplasia. After a partial hepatectomy, where a significant portion of the liver is removed, the remaining tissue launches a coordinated regenerative response. Growth factors like hepatocyte growth factor and epidermal growth factor, along with a cascade of cytokines, drive hepatocytes into DNA synthesis and division to restore the organ’s mass.8PubMed Central. Signals and cells involved in regulating liver regeneration
What makes this different from the hyperplasia seen in the prostate or endometrium is its self-limiting nature. The liver does not just keep growing indefinitely. Once the organ reaches approximately its original functional mass, the regenerative signals taper off and cell division slows back to baseline. The body has a remarkably precise sense of how much liver it needs, and the growth stops when that threshold is reached. This is why living-donor liver transplants work: the donated portion regrows in the recipient, and the remaining portion regrows in the donor.
Endocrine Gland Hyperplasia
Endocrine organs are particularly prone to hyperplasia because they are governed by feedback loops. When a signaling hormone stays elevated, the target gland can enlarge in response.
In congenital adrenal hyperplasia, the underlying problem is an enzyme deficiency in the adrenal glands, most often 21-hydroxylase. Without this enzyme, the glands cannot produce adequate cortisol. The lack of cortisol removes normal feedback on the brain’s signaling centers, which respond by pumping out more adrenocorticotropic hormone. That excess signaling drives the adrenal glands to enlarge as they try, unsuccessfully, to produce enough cortisol. A major downstream consequence is overproduction of adrenal androgens, which in children can accelerate bone maturation and lead to premature closure of growth plates.9The Journal of Clinical Endocrinology & Metabolism. Genetics and Pathophysiology of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
The thyroid offers another example. When thyroid-stimulating hormone receptors carry mutations that leave them permanently switched on, the thyroid cells proliferate even without a legitimate signal telling them to grow. This leads to toxic hyperplasia, where the gland enlarges and overproduces thyroid hormones, sometimes resulting in multinodular goiters that cause hyperthyroidism.10PubMed. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism Here, the hyperplasia is not driven by an external excess of stimulating hormone but by a genetic error that makes the gland think it is constantly being told to grow.
Skin and the Psoriasis Connection
The skin is constantly renewing itself, with keratinocytes in the basal layer dividing and migrating outward to replace cells shed from the surface. In psoriasis, this turnover goes into overdrive. Inflammatory signals, particularly a cytokine called IL-17, activate keratinocytes, which in turn produce their own inflammatory molecules and antimicrobial peptides. This creates a self-amplifying loop: immune cells stimulate keratinocytes, and activated keratinocytes recruit more immune cells.11PubMed Central. Advances in the pathogenesis of psoriasis: from keratinocyte perspective
The result is epidermal hyperplasia, the thickened, scaly plaques characteristic of the disease. Multiple factors feed into keratinocyte proliferation in psoriasis, including the inflammatory cytokine environment, the immune microenvironment, the skin microbiome, epigenetic changes, and metabolic signals.12iScience. Factors influencing the proliferation of keratinocytes in psoriasis Modern biologic therapies for psoriasis target specific cytokines in this loop, and their effectiveness at clearing plaques underscores just how central the inflammatory-hyperplastic feedback cycle is to the disease.
Blood Vessels and Intimal Hyperplasia
One of the most clinically frustrating forms of hyperplasia occurs inside blood vessels. After vascular surgery or the placement of a stent, the innermost layer of the vessel wall can thicken as smooth muscle cells migrate into it, proliferate, and secrete extra connective-tissue material. This process, called intimal hyperplasia, is a leading cause of restenosis, the re-narrowing of a vessel after it has been opened.13PubMed Central. Vascular smooth muscle cells in intimal hyperplasia, an update
The trigger is injury to the vessel wall during surgery. That injury sets off an inflammatory response, and smooth muscle cells that are normally quiescent shift into an active state. They lose their contractile identity and start behaving more like the cells you would find in a healing wound, migrating to the injury site and multiplying there. Researchers have explored anti-inflammatory compounds called resolvins that can dampen this response. In animal models, resolvins reduced smooth muscle cell proliferation and leukocyte recruitment at the injury site, and one resolvin cut neointimal hyperplasia by about a third over four weeks.14PubMed Central. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury Drug-eluting stents, which release anti-proliferative compounds directly into the vessel wall, were developed specifically to address this problem, and they have significantly reduced restenosis rates compared to bare-metal stents.
Drug-Induced Gingival Hyperplasia
Some medications cause hyperplasia as a side effect, and the gums are a surprisingly common site for it. Three drug classes in particular are linked to gingival overgrowth: the anti-seizure drug phenytoin, the immunosuppressant cyclosporine, and the blood pressure medication nifedipine. These drugs have very different chemical structures, which suggests the overgrowth is probably caused not by the drugs themselves but by a metabolic byproduct they share.15PubMed. Drug-induced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine
Cyclosporine-induced gingival overgrowth, the best studied of the three, appears to result from an interaction between the drug or its metabolites and susceptible gum fibroblasts. Plaque-induced gum inflammation seems to amplify this interaction, meaning that good oral hygiene can reduce the severity of the overgrowth even if the patient continues the medication.16PubMed Central. Cyclosporine A: Novel concepts in its role in drug-induced gingival overgrowth For patients on organ-transplant immunosuppression, switching from cyclosporine to an alternative drug is sometimes possible, and the gingival tissue often returns toward normal afterward.
When Hyperplasia Reverses and When It Progresses
A critical question with any hyperplasia is whether it will go away once the stimulus stops. In many cases, the answer is yes. Experimental work in mouse skin has shown that hyperplastic lesions driven by sustained activation of a growth-promoting gene regressed completely within about 25 days of turning that gene off. Normal cell differentiation resumed, excess blood vessels that had formed to feed the lesion disappeared, and the tissue became indistinguishable from normal skin.17Cell. Inducible Activation of c-Myc in Mouse Skin Restores Normal Differentiation and Causes Rapid Regression of Papillomas This reversibility is what fundamentally separates hyperplasia from cancer in most contexts: remove the driving signal and the tissue returns to normal.
But the picture is not always that clean. Endometrial hyperplasia with atypical features carries a meaningful risk of progressing to endometrial carcinoma. Chronic inflammation-driven hyperplasia in the stomach lining is associated with gastric cancer risk. The longer an abnormal growth stimulus persists, the more opportunities there are for additional genetic mutations to accumulate in the proliferating cells, potentially tipping them from regulated overgrowth into unregulated malignancy. This is why clinicians treat certain hyperplasias aggressively even though they are technically benign: the window between reversible overgrowth and irreversible transformation can narrow over time.
How Pathologists Tell Hyperplasia from Cancer
Under a microscope, distinguishing hyperplasia from early cancer can be genuinely difficult. Both involve increased cell numbers, and in tissues like the endometrium or thyroid, the boundary between them is not always obvious from cell shape alone. Pathologists increasingly rely on specific protein markers detected through immunohistochemical staining to make the call.
In the endometrium, markers like Ki-67, which flags actively dividing cells, and p53 and PTEN, which are involved in tumor suppression, help distinguish hyperplastic tissue from carcinoma. Their expression patterns differ between benign overgrowth and malignant transformation, giving pathologists additional data points beyond what they can see in a standard tissue stain.18European Journal of Cardiovascular Medicine. Study of Immunohistochemical markers KI67, p53 and PTEN in differentiating endometrial hyperplasia from endometrial carcinoma
In the thyroid, the challenge arises when papillary hyperplasia looks structurally similar to papillary thyroid carcinoma. A marker called HBME-1 has shown promise here: while other markers like cytokeratin 19 and galectin-3 stain positively in both cancerous and non-cancerous thyroid tissue, HBME-1 is uncommon in benign cases and may help clinicians sort ambiguous diagnoses.19PubMed. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1 These diagnostic tools matter because the treatment for hyperplasia and cancer can be dramatically different, and overdiagnosis can subject a patient to unnecessary surgery or radiation.
The Physical Environment and Stem Cell Behavior
Hyperplasia is not driven by hormones and cytokines alone. The physical stiffness of the tissue surrounding cells also influences how those cells behave. The extracellular matrix, the scaffolding that holds tissues together, sends mechanical signals through pathways involving integrins and other sensors on the cell surface. Stiffer environments can push fibroblasts toward more inflammatory and proliferative behavior, which is relevant to conditions where fibrosis and hyperplasia overlap.20PubMed Central. Extracellular Matrix Stiffness: Mechanotransduction and Mechanobiological Response-Driven Strategies for Biomedical Applications Targeting Fibroblast Inflammation
Stem cells add another layer of complexity. In tissues with high turnover, like the intestinal lining, adult stem cells are responsible for continually replenishing the cell population. When the signaling pathways that control stem cell division and maturation become deregulated, the result can be hyperplasia that tips toward tumor formation. The Wnt signaling pathway, which plays a central role in intestinal stem cell behavior, is a well-studied example: when Wnt signaling is constitutively active, the intestinal epithelium can undergo hyperplastic expansion that, if unchecked, contributes to colorectal tumor development.21PubMed Central. Wnt signalling and its role in stem cell-driven intestinal regeneration and hyperplasia This connection between normal regeneration and abnormal overgrowth is part of what makes the intestine such a useful system for studying how tissues stay balanced, and what happens when they do not.
Why “Benign” Does Not Always Mean “Ignore It”
One of the most common misconceptions about hyperplasia is that because it is not cancer, it does not require attention. In some cases that is true: physiological hyperplasia like breast changes during pregnancy resolves on its own. But in other settings, the label “benign” describes where you are on a spectrum, not a guarantee about where you will stay. Endometrial hyperplasia with atypia has a recognized progression rate to carcinoma. BPH, while not a cancer precursor, can cause urinary obstruction severe enough to require surgery. Intimal hyperplasia after vascular procedures can close off a repaired artery and undo the benefits of the original intervention.
The practical upshot is that the clinical response to hyperplasia depends heavily on its location, its cause, and whether it shows features suggestive of instability. A pathology report identifying simple hyperplasia without atypia in the endometrium might warrant monitoring and hormonal management. The same report noting atypical features might prompt more aggressive treatment. In the prostate, symptoms often guide decisions: mild BPH may need nothing more than periodic check-ups, while bothersome urinary symptoms warrant medical or surgical therapy. The word “hyperplasia” on its own tells you something about what the tissue is doing but almost nothing about what you should do next without knowing the full clinical picture.